Perspective from Sanjit S. Jolly, MD, MSc
October 12, 2015
2 min read

ABSORB III: Bioresorbable scaffold noninferior to cobalt-chromium stent

Perspective from Sanjit S. Jolly, MD, MSc
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN FRANCISCO — An everolimus-eluting bioresorbable vascular scaffold was noninferior to a cobalt-chromium everolimus-eluting stent for target lesion failure in patients with noncomplex obstructive CAD at 1 year in the ABSORB III trial.

“The primary endpoint for this trial has been met,” Dean J. Kereiakes, MD, FACC, medical director at The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, and a member of the Cardiology Today’s Intervention Editorial Board, said in a presentation. “The [TLF] components of cardiac death, target vessel MI and ischemia-driven target lesion revascularization were not significantly different between the devices.”

Dean J. Kereiakes, MD, FACC, FSCAI

Dean J. Kereiakes

The large-scale multicenter trial randomly assigned 2,008 patients with stable or unstable angina in a 2:1 ratio to an everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular; n = 1,322) or a cobalt-chromium everolimus-eluting stent (Xience, Abbott Vascular; n = 686).

The investigators sought TLF including CV death, target vessel MI or ischemia-driven TLR as primary endpoints, testing for noninferiority at a margin of 4.5 percentage points for risk difference as well as superiority.

At 1 year, 7.8% of patients with bioresorbable scaffold experienced TLF vs. 6.1% of patients with cobalt-chromium stent (difference, 1.7 percentage points; 95% CI, –0.5 to 3.9).

No differences were observed between the bioresorbable scaffold and cobalt-chromium stent groups for CV death (0.6% vs. 0.1%; P = .29), target vessel MI (6% vs. 4.6%; P = .18) or ischemia-driven TLR (3% vs. 2.5%; P = .5).

The powered secondary endpoints of angina, all revascularization and ischemia-driven TVR were similar between the devices. Similar results were seen for device thrombosis, occurring in 1.5% of patients with bioresorbable scaffold and 0.7% of patients with cobalt-chromium stent (P = .13).

“The ABSORB III trial has demonstrated safety and efficacy of Absorb [bioresorbable vascular scaffold] at 1 year in patients with stable CAD and stabilized ACS,” Kereiakes said. “Longer-term evaluation is ongoing to determine if Absorb improves late outcomes compared to Xience.” – by Allegra Tiver


Ellis SG, et al. N Engl J Med. 2015;doi:10.1056/NEJMoa1509038.

Kereiakes DJ. Am Heart J. 2015;doi:10.1016/j.ahj.2015.07.013.

Kereiakes DJ. ABSORB III: A prospective randomized trial of an everolimus-eluting bioresorbable scaffold vs. an everolimus-eluting metallic stent in patients with coronary artery disease. Presented at: TCT 2015; Oct. 11-15, 2015; San Francisco.

Disclosure: Kereiakes reports multiple financial relationships in consulting, research and speakers capacities with Abbott Vascular, Boston Scientific Corp. and Svelte Medical Systems Inc., as well as using the off-label bioresorbable vascular scaffold to treat atherosclerosis.